Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis

Core Evidence
Minoru InomataArata Azuma

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. The molecular mechanisms involved in the progression of IPF are not fully understood; however, the platelet-derived growth factor (PDGF)/PDGF receptor pathway is thought to play a critical role in fibrogenesis of the lungs. Other growth factors, including fibroblast growth factor and vascular endothelial growth factor, are also thought to contribute to the pathogenesis of pulmonary fibrosis. Nintedanib is an inhibitor of multiple tyrosine kinases, including receptors for PDGF, fibroblast growth factor, and vascular endothelial growth factor. In the Phase II TOMORROW trial, treatment with 150 mg of nintedanib twice daily showed a trend to slow the decline in lung function and significantly decrease acute exacerbations in patients with IPF, while showing an acceptable safety profile. The Phase III INPULSIS trials demonstrated a significant decrease in the annual rate of decline in forced vital capacity in IPF patients treated with 150 mg nintedanib twice daily. In the INPULSIS-2 trial, the time to the first acute exacerbation significantly increased in IPF patients who were treated with 150 mg of nintedanib twice daily. Pirfenidone, another antifibr...Continue Reading

Citations

Nov 4, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Robert Roskoski
Mar 16, 2018·American Journal of Physiology. Lung Cellular and Molecular Physiology·Elizabeth F RedenteDavid W H Riches
Feb 2, 2021·Frontiers in Medicine·Natalia JarzebskaPeter M Spieth
Jan 27, 2017·Journal of Medicinal Chemistry·Yi-Min LiuJing-Ping Liou

❮ Previous
Next ❯

Methods Mentioned

BETA
bronchoalveolar lavage

Software Mentioned

TOMORROW

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

Therapeutic Advances in Respiratory Disease
Mariano E MazzeiHarold R Collard
The New England Journal of Medicine
Luca RicheldiINPULSIS Trial Investigators
The European Respiratory Journal
Friedrich GrimmingerCarlo Vancheri
© 2021 Meta ULC. All rights reserved